Determining the factors for interhospital transfer in advanced heart failure cases.
Advanced heart failure
Distance
Interhospital transfer
Journal
International journal of cardiology. Heart & vasculature
ISSN: 2352-9067
Titre abrégé: Int J Cardiol Heart Vasc
Pays: Ireland
ID NLM: 101649525
Informations de publication
Date de publication:
Jun 2022
Jun 2022
Historique:
received:
17
02
2022
revised:
15
04
2022
accepted:
18
04
2022
entrez:
23
5
2022
pubmed:
24
5
2022
medline:
24
5
2022
Statut:
epublish
Résumé
There are some patients with advanced heart failure (HF), for whom implantable left ventricular assist device (LVAD) or heart transplantation (HTx) should be considered. Some of them need to be transferred between hospitals. There are few reports on the interhospital transfer of patients with advanced HF and their subsequent clinical course.In this study, we investigated the characteristics and clinical course of patients transferred to a LVAD/HTx center, focusing on the distance between hospitals. We retrospectively examined 141 patients who were transferred to our hospital, considering the indications of LVAD implantation or HTx. We divided the patients into two groups: those referred <33 km (short-distance) and those referred more than 33 km (long-distance). The primary outcome was the composite outcome of increased catecholamine dose, mechanical support, or renal dysfunction within 1 week of transfer. Continuous catecholamine infusion was significantly more common in patients in the long-distance group, whereas extracorporeal membrane oxygenation (ECMO) placement was significantly more common in short-distance group.Patients transferred via long distance had significantly higher rates of increased catecholamine doses, mechanical support including intra-aortic balloon pumping (IABP) and ECMO, and renal dysfunction within 1 week of transfer than patients transferred via short distance. Multivariate analysis showed that low body mass index (BMI) and long distance were independent predictive factors for the primary outcome. When patients with advanced HF are transferred from far distant hospitals or with low BMI, it may be necessary to devise various measures for interhospital transport.
Sections du résumé
Background
UNASSIGNED
There are some patients with advanced heart failure (HF), for whom implantable left ventricular assist device (LVAD) or heart transplantation (HTx) should be considered. Some of them need to be transferred between hospitals. There are few reports on the interhospital transfer of patients with advanced HF and their subsequent clinical course.In this study, we investigated the characteristics and clinical course of patients transferred to a LVAD/HTx center, focusing on the distance between hospitals.
Methods
UNASSIGNED
We retrospectively examined 141 patients who were transferred to our hospital, considering the indications of LVAD implantation or HTx. We divided the patients into two groups: those referred <33 km (short-distance) and those referred more than 33 km (long-distance). The primary outcome was the composite outcome of increased catecholamine dose, mechanical support, or renal dysfunction within 1 week of transfer.
Results
UNASSIGNED
Continuous catecholamine infusion was significantly more common in patients in the long-distance group, whereas extracorporeal membrane oxygenation (ECMO) placement was significantly more common in short-distance group.Patients transferred via long distance had significantly higher rates of increased catecholamine doses, mechanical support including intra-aortic balloon pumping (IABP) and ECMO, and renal dysfunction within 1 week of transfer than patients transferred via short distance. Multivariate analysis showed that low body mass index (BMI) and long distance were independent predictive factors for the primary outcome.
Conclusions
UNASSIGNED
When patients with advanced HF are transferred from far distant hospitals or with low BMI, it may be necessary to devise various measures for interhospital transport.
Identifiants
pubmed: 35601528
doi: 10.1016/j.ijcha.2022.101035
pii: S2352-9067(22)00084-7
pmc: PMC9118470
doi:
Types de publication
Journal Article
Langues
eng
Pagination
101035Informations de copyright
© 2022 The Author(s).
Déclaration de conflit d'intérêts
The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.
Références
J Intensive Care Soc. 2020 Feb;21(1):33-39
pubmed: 32284716
Can J Cardiol. 2018 Jul;34(7):863-870
pubmed: 29960615
Perfusion. 2008 Mar;23(2):101-6
pubmed: 18840578
Curr Pharm Des. 2020;26(14):1571-1583
pubmed: 31878852
Eur J Heart Fail. 2017 May;19(5):595-602
pubmed: 28198133
J Am Heart Assoc. 2020 Aug 4;9(15):e016952
pubmed: 32720569
JAMA Netw Open. 2020 Jul 1;3(7):e2011044
pubmed: 32692370
J Crit Care. 2007 Dec;22(4):290-5
pubmed: 18086399
Circ Cardiovasc Qual Outcomes. 2014 Sep;7(5):780-2
pubmed: 25205785
J Crit Care. 2009 Mar;24(1):108-13
pubmed: 19272546
Eur J Heart Fail. 2018 Nov;20(11):1505-1535
pubmed: 29806100
Eur Heart J. 2021 Feb 11;42(6):681-683
pubmed: 33447845
Heart Fail Rev. 2017 Sep;22(5):559-564
pubmed: 28670652
Circ Cardiovasc Interv. 2015 Sep;8(9):e002477
pubmed: 26338881
Crit Pathw Cardiol. 2014 Mar;13(1):1-5
pubmed: 24526143
J Am Heart Assoc. 2019 Nov 19;8(22):e013592
pubmed: 31707940
J Gen Intern Med. 2020 Oct;35(10):2939-2946
pubmed: 32700216
ESC Heart Fail. 2018 Jun;5(3):322-331
pubmed: 29388735
Open Heart. 2017 Mar 8;4(1):e000547
pubmed: 28409010
Circulation. 2021 Oct 12;144(15):e238-e250
pubmed: 34503343